8-K: Shuttle Pharmaceuticals Engages Bowery Consulting Group to Bolster Growth and Investor Strategy

Shuttle Pharmaceuticals Holdings, Inc. has entered into a consulting agreement with Bowery Consulting Group Inc. to enhance its business strategy, investor relations, and capital-raising efforts.

Summary

• Shuttle Pharmaceuticals Holdings, Inc. has entered into a consulting services agreement with Bowery Consulting Group Inc. effective March 21, 2025.
• Bowery Consulting will provide services including research, due diligence, analysis, and advising on scaling activities to reach milestones and goals.
• The consultant will also develop market messaging, growth and capital raising strategies, and outline investor and funding strategies.
• The consulting agreement has a term of six months.
• Shuttle Pharmaceuticals will pay Bowery Consulting a fee of $260,000, payable after the company regains compliance with Nasdaq Listing Rules.

Sentiment

Score: 7

Explanation: The document indicates a proactive approach to improving business strategy and investor relations, which is generally positive. However, the contingent payment on Nasdaq compliance introduces some uncertainty.

Positives

• The engagement of Bowery Consulting Group aims to improve Shuttle Pharmaceuticals' business strategy and investor relations.
• The consulting services are intended to support the company in reaching milestones and goals.
• Bowery Consulting's expertise could help Shuttle Pharmaceuticals attract investors and secure funding for growth.

Negatives

• The consulting fee of $260,000 represents a significant expense for Shuttle Pharmaceuticals.
• Payment of the fee is contingent on the company regaining compliance with Nasdaq Listing Rules, indicating potential financial or operational challenges.

Risks

• The success of the consulting engagement depends on Bowery Consulting's ability to deliver effective strategies and advice.
• There is a risk that the consulting services may not result in the desired improvements in business performance or investor relations.
• The company's ability to pay the consulting fee is dependent on regaining Nasdaq compliance, which may be uncertain.

Future Outlook

The consulting agreement suggests that Shuttle Pharmaceuticals is actively seeking to improve its business strategy, investor relations, and capital-raising efforts to support future growth.

Management Comments

• Chris Cooper, Interim Co-Chief Executive Officer, signed the report on behalf of Shuttle Pharmaceuticals Holdings, Inc.

Industry Context

The engagement of a consulting firm is a common practice for companies seeking to improve their business strategy, investor relations, and capital-raising efforts, particularly in the e-commerce/technology sector.

Comparison to Industry Standards

• Consulting fees for similar services in the e-commerce/technology sector can vary widely depending on the scope and complexity of the engagement.
• Companies like McKinsey, Bain, and Boston Consulting Group often charge significantly higher fees for their services, but smaller firms like Bowery Consulting Group may offer more cost-effective solutions.
• The success of such engagements is often measured by improvements in key performance indicators such as revenue growth, profitability, and investor sentiment.

Stakeholder Impact

• Shareholders may benefit from improved business strategy and investor relations.
• Employees may experience changes in their roles or responsibilities as a result of the consulting engagement.
• Customers may see improvements in products or services as a result of the company's growth initiatives.

Next Steps

• Bowery Consulting Group will begin providing consulting services to Shuttle Pharmaceuticals.
• Shuttle Pharmaceuticals will work towards regaining compliance with Nasdaq Listing Rules to trigger payment of the consulting fee.
• The company will implement the strategies and recommendations provided by Bowery Consulting Group.

Key Dates

Keywords

consulting services, Shuttle Pharmaceuticals, Bowery Consulting Group, capital raising, investor strategy, due diligence, market messaging, Nasdaq compliance, growth strategy